Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Lev Asherov

Internal Medicine Pueblo, CO Medical Doctor

NPI 1164685228 CMS profile 652874

1600 N Grand Ave, Suite 245, Pueblo, CO 81003

Open in the dashboard

General payments

$925

69 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Lev Asherov of Pueblo, CO is reported in the CMS Open Payments database as having received $925 across 69 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 69th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $17 1
2023 General $455 37
2022 General $183 11
2021 General $49 3
2020 General $37 3
2019 General $185 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lev Asherov
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Lev Asherov were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Lev Asherov Internal Medicine median Middle half National median
2019 $185 $159 $48–$570 $163
2020 $37 $119 $33–$402 $114
2021 $49 $135 $37–$521 $132
2022 $183 $141 $42–$496 $149
2023 $455 $149 $45–$519 $160
2024 $17 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. GlaxoSmithKline, LLC. $131 20 payments
  2. Pfizer Inc. $110 7 payments
  3. AbbVie, Inc. $97 4 payments
  4. AstraZeneca Pharmaceuticals LP $89 6 payments
  5. Novartis Pharmaceuticals Corporation $58 3 payments
  6. Novo Nordisk Inc $54 4 payments
  7. Sunovion Pharmaceuticals Inc. $44 2 payments
  8. Janssen Pharmaceuticals, Inc $40 3 payments
  9. Amgen Inc. $39 3 payments
  10. Exact Sciences Corporation $34 2 payments
  11. Other $230 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $913 68 payments
  2. Education $12 1 payment
Products named General payments · program years 2019–2024
  1. TRELEGY ELLIPTA $101 15 payments
  2. PAXLOVID $68 4 payments
  3. VRAYLAR $59 2 payments
  4. ELIQUIS $58 3 payments
  5. Ozempic $54 4 payments
  6. COMIRNATY $51 3 payments
  7. FARXIGA $47 3 payments
  8. GEMTESA $44 2 payments
  9. SYMBICORT $42 3 payments
  10. XARELTO $40 3 payments
  11. Other $833 59 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 189 drugs

Part D claims

17,932

Median for Internal Medicine: 777

Drug cost

$2,364,509

Median for Internal Medicine: $73,373

Branded share of claims

23.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 351 $419,002
Mounjaro Tirzepatide Brand 298 $380,615
Eliquis Apixaban Brand 143 $210,161
Jardiance Empagliflozin Brand 171 $196,759
Trulicity Dulaglutide Brand 151 $195,580
Xarelto Rivaroxaban Brand 59 $77,734
Farxiga Dapagliflozin Propanediol Brand 53 $68,209
Myrbetriq Mirabegron Brand 67 $61,311
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 39 $56,422
Januvia Sitagliptin Phosphate Brand 32 $45,705

The 10 drugs with the highest cost, of 189 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$256,789

Of which drugs: $63,317

Medicare patients

522

Average age 76

Services billed

6,627

226 women, 296 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 45%
Diabetes 30%
Depression 26%
Osteoporosis 20%
Chronic kidney disease 19%
Ischemic heart disease 18%
COPD 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 19 1,920 $39,113
Pcv20 vaccine im 90677 Office 26 26 $7,557
Vaccine for influenza for injection into muscle 90662 Office 46 48 $3,888

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

69 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record